Fundraising FoxFrazier Life Sciences — Full Portfolio
213 tracked investments · page 2 of 2 · listed companies and verified rows first
Tubulis develops antibody-drug conjugates (ADCs) for cancer treatment, using proprietary conjugation platform technologies to create tumor-targeting therapeutics.
BiotechDeep TechMedical DevicesPlanegg-Martinsried, DE
Dominik Schumacher(Co-founder & CEO)inJonas Helma-Smets(Co-founder & Chief Scientific Officer)Christian Hackenberger(Scientific Co-founder)
Co-investorsAndera PartnersBioMedPartnersEQT Life SciencesNexTech VenturesAscenta CapitalBayern Kapital+8 more
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalNew Enterprise Associates (NEA)Sofinnova Partners+4 more
BiotechHealthtechMedical Devices
Vinnie Milanoin
Co-investorsOak Investment Partners
VIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases.
BiotechHealthtechMedical Devices
John Amos(Chief Executive Officer)inSantosh T. Varghese(President VIVUS Global Pharmaceutical Development & Chief Medical Officer)in
Co-investorsAisling Capital
ZEMDRI (plazomicin) is an aminoglycoside antibiotic injection indicated for adults with complicated urinary tract infections, including pyelonephritis, caused by certain susceptible microorganisms.
BiotechHealthtech
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Trubion PharmaceuticalsTularikUrica TherapeuticsVectivBioVentiRx PharmaceuticalsXenoportZavante TherapeuticsZymogenetics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.